Trimodal prehabilitation for people with gastrointestinal cancer
Official title: TRIMODAL PREHABILITATION PROGRAM IN PATIENTS WITH GASTROINTESTINAL CANCER DURING NEOADJUVANT TREATMENT: A PILOT STUDY
Run by Puerta de Hierro University Hospital · NCT07281248 · Data updated 2026-11-12
This program tests whether a three-part pre-surgery program combining physical training, nutritional support, and motivational coaching can improve fitness and recovery for adults with stage I–III gastrointestinal cancer scheduled for abdominal surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Puerta de Hierro University Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Madrid, Madrid) |
| Status | Recruiting |
| Started | August 28, 2025 |
| Main results expected | September 1, 2026 |
| Study ends | September 1, 2027 |
| Registry record updated | December 15, 2025 |
| Trial ID | NCT07281248 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with non-metastatic stage I–III gastrointestinal cancer, ECOG 0–2, able to complete a mile-time test and attend preoperative sessions at the Madrid site.
✕Probably not a fit
Patients with metastatic disease, ECOG >2, inability to perform exercise testing, or those requiring urgent/emergency surgery are unlikely to benefit from this prehabilitation program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with stage I–III gastrointestinal cancer who are planned for abdominal surgery will be offered a trimodal prehabilitation program that combines physical training, nutritional support, and motivational coaching. The physical component emphasizes graded aerobic and resistance exercises with flexibility and balance work, personalized after a baseline functional assessment and a motivational interview. Exercise targets follow WHO-style recommendations (progressive moderate-to-vigorous activity, 150–300 minutes/week when tolerated) and are adapted to the patient’s capacity; supervised and home-based elements are used. The intervention is delivered at Hospital Universitario Puerta de Hierro Majadahonda and excludes patients with metastatic disease or poor performance status.
Why it matters
Potential benefit: If successful, the program could improve patients' fitness before surgery, reduce postoperative complications, and shorten hospital recovery.
How similar studies have gone: Prior multimodal prehabilitation programs, particularly in colorectal and other abdominal surgery, have shown improvements in preoperative fitness and reduced complications, though findings vary between trials.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * More than 18 years old * ECOG 0-2 * Being able to complete the mile-time test * Stages I-III * Being able to understand the informed consent * Gastrointestinal cancer diagnosed Exclusion Criteria: * Metastatic cancer
Where it's running
-
Hospital Universitario Puerta de Hierro Majadahonda
Madrid, Madrid, Spain Recruiting
Study contacts
- Principal investigator: Ana Ruiz Casado Principal Investigator, PhD, MD — Hospital Universitario Puerta de Hierro
- Study coordinator: Ana Ruiz Casado MD, PhD, Medical oncologist
- Email: arcasado@salud.madrid.org
- Phone: 607890187
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if preoperative anxiety affects recovery after major digestive cancer surgery
This study tests whether anxiety before surgery is linked to more complications after major digestive cancer operations in French-speaking adults.
-
Benchmarking AI language models against tumor boards for oncology treatment decisions
This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.
-
PF-08634404 plus chemotherapy for adults with metastatic colorectal cancer
This trial will test whether adding a new drug called PF-08634404 to standard chemotherapy helps adults whose colorectal cancer has spread.
-
Multimodal ablation with Tislelizumab, lenvatinib and TACE for unresectable primary liver cancer
This trial will test whether combining multimodal ablation with Tislelizumab (a PD‑1 antibody), lenvatinib, and TACE helps people with unresectable primary liver cancer.
-
Personalized mRNA vaccine for advanced digestive system cancers
This study is testing a new personalized mRNA vaccine for people with advanced digestive system cancers to see if it works better when used with standard treatment.
-
Personalized mRNA vaccine for patients with resected digestive system tumors
This study is testing a personalized mRNA vaccine combined with standard treatment to see if it helps patients who have had surgery for advanced digestive system cancers feel better and improve their outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.